US 12,202,886 B2
Neutralizing antibodies to GP120 and their use
Mark Connors, Bethesda, MD (US); Jinghe Huang, Derwood, MD (US); Byong Ha Kang, Rockville, MD (US); John Mascola, Rockville, MD (US); Elise Ishida, Chevy Chase, MD (US); Tongqing Zhou, Boyds, MD (US); Peter Kwong, Washington, DC (US); and Anqi Zheng, Boyds, MD (US)
Assigned to THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services, Bethesda, MD (US)
Filed by The United States of America, as represented by the Secretary, Department of Health and Human Services, Bethesda, MD (US)
Filed on Jun. 30, 2022, as Appl. No. 17/855,553.
Application 17/855,553 is a continuation of application No. 17/358,522, filed on Jun. 25, 2021, abandoned.
Application 17/358,522 is a continuation of application No. 16/786,267, filed on Feb. 10, 2020, abandoned.
Application 16/786,267 is a continuation of application No. 15/559,791, granted, now 10,562,960, issued on Feb. 18, 2020, previously published as PCT/US2016/023145, filed on Mar. 18, 2016.
Claims priority of provisional application 62/250,378, filed on Nov. 3, 2015.
Claims priority of provisional application 62/136,228, filed on Mar. 20, 2015.
Prior Publication US 2023/0060304 A1, Mar. 2, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/10 (2006.01); A61P 31/18 (2006.01); C07K 16/28 (2006.01); C07K 16/46 (2006.01); G01N 33/569 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/1063 (2013.01) [A61P 31/18 (2018.01); C07K 16/2809 (2013.01); C07K 16/468 (2013.01); G01N 33/56988 (2013.01); A61K 2039/505 (2013.01); A61K 2039/545 (2013.01); C07K 2317/21 (2013.01); C07K 2317/31 (2013.01); C07K 2317/52 (2013.01); C07K 2317/76 (2013.01); G01N 2333/162 (2013.01); G01N 2800/26 (2013.01)] 11 Claims
 
1. An isolated monoclonal antibody, comprising
a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 1;
a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 2; and
an IgG constant domain comprising M428L and N434S mutations, wherein the antibody binds to CD4 binding site on HIV-1 gp120.